Catalyst Wire Dossier Catalyst Wire Dossier

Murine T-cell receptor-engineered peripheral blood lymphocytes targeting G12D KRAS (HLA-A*11:01)

· National Cancer Institute
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Murine T-cell receptor-engineered peripheral blood lymphocytes targeting G12D KRAS (HLA-A*11:01), covering 2026-03-19 to 2026-03-19. Get the full timeline:

Most recent: Clinical Trial Update: Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients [Phase 1, Phase 2]

See pricing